Search
Tafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigationalTafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. … [A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.
Pegsunercept
go.drugbank.com/drugs/DB06611InvestigationalPegsunercept is used for treating rheumatoid arthritis. Phase II clinical trials were completed in January 2010.
Categories: Compounds used in a research, industrial, or household settingMepolizumab
go.drugbank.com/drugs/DB06612ApprovedInvestigationalEosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typically defined as absolute eosinophil levels of 1500/mm<sup>3</sup> or more) is associated with a spectrum … [A221048, A221053, A221058, A221063, A221068, L16518] Mepolizumab is a fully-humanized recombinant IgG1 kappa monoclonal antibody directed against IL-5 produced in Chinese hamster ovary cells.
Bosutinib
go.drugbank.com/drugs/DB06616ApprovedInvestigationalPhiladelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein. … Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexFlupirtine
go.drugbank.com/drugs/DB06623InvestigationalFlupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe.
IMA901
go.drugbank.com/drugs/DB06628InvestigationalIMA901 is a vaccine consists of tumor-associated peptides (TUMAPs).
Isavuconazonium
go.drugbank.com/drugs/DB06636ApprovedInvestigationalIsovuconazonium has excellent oral bioavailability, predictable pharmacokinetics, and a good safety profile, making it a reasonable alternative to its few other competitors on the market. … Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis
Bevasiranib
go.drugbank.com/drugs/DB06642InvestigationalBevasiranib is a small interfering RNA (siRNA) targeting vascular endothelial growth factor A (VEGF-A).
Categories: Compounds used in a research, industrial, or household settingGMK
go.drugbank.com/drugs/DB06661ExperimentalGMK vaccine (a ganglioside conjugate vaccine coupled to keyhole limpet hemocyanin and formulated with the adjuvant QS-21) for the potential treatment of melanoma
Asoprisnil
go.drugbank.com/drugs/DB06680InvestigationalAsoprisnil (J867) is a selective progesterone receptor modulator. It can be used to treat progesterone sensitive myomata.